



Tokyo, December 14, 2018

FOR IMMEDIATE RELEASE

The date for terminating the license agreements by which JT grants Torii the exclusive rights to market the Six Anti-HIV Drugs in Japan has been set.

Today, Torii Pharmaceutical Co., Ltd (Torii) (TSE:4551) has announced that the date for terminating the license agreements by which JT grants Torii the exclusive rights to market the Six Anti-HIV Drugs※ (Current HIV Drugs) in Japan has been set.

1. Schedule

The date of termination of the license agreements will be January 1, 2019.

Since January 1, 2019, Gilead Sciences K.K. (Gilead K.K.) will be responsible for providing information about Current HIV Drugs to medical institutions. While, until Gilead K.K. completely succeeds JT's marketing approval of the Current HIV Drugs in Japan, as a transitional measure, Torii is responsible for distribution

2. Impact on Financial Performance

The effects of this termination of the license agreements on the business performance of Torii's in this fiscal year will be immaterial.

Torii will disclose the forecasts including the effects of this termination for FY2019 as same as reporting financial results for this fiscal year.

※Six Anti-HIV Drugs : “Viread® Tablets 300mg” “Emtriva® Capsules 200mg” “Truvada® Combination Tablets” “Stribild® Combination Tablets” “Genvoya® Combination Tablets” “Descovy® Combination Tablets LT/HT”

Contact for Torii Pharmaceutical Co., Ltd.:
Corporate Planning Department
(Public Relations)
Torii Pharmaceutical Co., Ltd.
Tokyo: +81-3-3231-6814